Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Parent Training Complements Medication for Treating Children With Pervasive Developmental Disorders - (DGNews)
    Psychotropic Medications Associated With Risk of Falls in Older Adults - (DGNews)
    FDA Approves Aripiprazole to Treat Irritability Associated With Autistic Disorder - (DGNews)
    FDA Approves Ziprasidone for Adjunctive Maintenance Treatment of Bipolar Disorder - (DGNews)
    Aripiprazole Generally Safe, Tolerable for Children With Autism-Related Irritability: Presented at AACAP - (DGDispatch)

    News archive

     Recent webcasts/CME - Psychiatry Other

    Webcasts/CME archive

     Recent cases - Psychiatry Other
      Munchausen Syndrome In The Emergency Department Mostly Difficult, Sometimes Easy To Diagnose: A Case Report And Review Of The Literature
      Female Sexual Dysfunction as a Comorbid Illness
      11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
      Comorbidity of Asperger's Syndrome and Bipolar Disorder
      Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report

      Cases archive
        




      my personal edition > psychiatry other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Paroxetine Demonstrates Continued Efficacy In Treatment Of Obsessive-Compulsive Disorder: Presented at WCP

      By Bruce Sylvester
      Special to DG News

      YOKOHAMA, JAPAN -- September 2, 2002 -- Short and long-term paroxetine treatment of patients with obsessive-compulsive disorder (OCD) results in a statistically significantly greater proportion of these patients attaining remission, researchers reported at the World Congress of Psychiatry in Yokohama.

      The investigators made a retrospective analysis of the paroxetine OCD clinical database, evaluating it specifically for remission data.

      Two of three short-term studies (12-week) were flexible dose trials (20-60mg/day), while the third was a fixed-dose trial (20, 40 and 60 mg/day). For the purpose of this retrospective analysis, the researchers combined data from these paroxetine groups.

      The investigators included data from two long-term (12 month) relapse-prevention studies. The studies were extensions of two of the short-term studies. Responders to 12 weeks of paroxetine treatment received six months of open-label paroxetine, and were then randomized to receive either paroxetine or placebo for a further six months during the double-blind phase of the study.

      For both the long and short-term studies, remission was defined as = 70 percent reduction from baseline in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score and CGI-Global Improvement score of 1 ("very much improved").

      In the three 12-week studies involving a total of 790 subjects, more paroxetine-treated patients achieved >70 percent reduction from baseline in Yale-Brown Obsessive Compulsive Scale (YBOCS) score than placebo subjects (10.6 percent vs 5.3 percent; p=0.015), and more paroxetine-treated patients achieved a CGI-Global Improvement (CGI) score of 1 than placebo (15.2 percent vs 7.3 percent; p=0.002).

      In the two 12-month relapse prevention studies, the original investigators had randomized 138 responders to 12 weeks open-label paroxetine treatment or placebo. Remission rates remained sustained in paroxetine subjects but fell in the subjects switched to placebo (>70 percent reduction in YBOCS: 32.4 percent paroxetine vs 11.4 percent placebo, p=0.004; CGI score of 1: 45.6 percent paroxetine vs 21.4 percent placebo, p=0.004).

      "These findings confirm the efficacy of paroxetine in OCD and demonstrate the benefit of continued long-term therapy," the authors concluded.

      The study was supported by GlaxoSmithKline Pharmaceuticals.



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send